Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 16610, Prague, Czech Republic.
Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 14220, Prague, Czech Republic.
Chembiochem. 2021 Sep 14;22(18):2741-2761. doi: 10.1002/cbic.202100121. Epub 2021 May 28.
This review describes recent progress in the design and development of inhibitors of human carbonic anhydrase IX (CA IX) based on space-filling carborane and cobalt bis(dicarbollide) clusters. CA IX enzyme is known to play a crucial role in cancer cell proliferation and metastases. The new class of potent and selective CA IX inhibitors combines the structural motif of a bulky inorganic cluster with an alkylsulfamido or alkylsulfonamido anchor group for Zn ion in the enzyme active site. Detailed structure-activity relationship (SAR) studies of a large series containing 50 compounds uncovered structural features of the cluster-containing inhibitors that are important for efficient and selective inhibition of CA IX activity. Preclinical evaluation of selected compounds revealed low toxicity, favorable pharmacokinetics and ability to reduce tumor growth. Cluster-containing inhibitors of CA IX can thus be considered as promising candidates for drug development and/or for combination therapy in boron neutron capture therapy (BNCT).
本文综述了基于笼状碳化硼和钴双(二硼烷)簇的人碳酸酐酶 IX(CA IX)抑制剂的设计和开发的最新进展。已知 CA IX 酶在癌细胞增殖和转移中起关键作用。新型强效和选择性 CA IX 抑制剂将大体积无机簇的结构基序与酶活性位点中的 Zn 离子的烷基磺酰胺或烷基磺酰胺锚定基团结合在一起。对包含 50 种化合物的大型系列化合物的详细结构-活性关系 (SAR) 研究揭示了含簇抑制剂的结构特征,这些特征对于有效和选择性抑制 CA IX 活性非常重要。对选定化合物的临床前评估显示出低毒性、良好的药代动力学和降低肿瘤生长的能力。因此,含簇 CA IX 抑制剂可被视为药物开发和/或硼中子俘获治疗(BNCT)联合治疗的有前途的候选药物。